I finally bailed out on AMPE after 3 years. Two failed Phase 3 trials and a management team that has over promised but NEVER delivered. It is a mickey mouse team.
If the next Phase 3 trial fails, they go Chapter 11 and stock zeros out. It is now uninvestable, I wouldn't be surprised if their 2 big shareholders - Act & Knoll - bailed out on Bloody Monday.
...he mercifully left the AMPE board after the stock imploded.
Dr's Schwappach in Denver & Dr Ervin in K.C. will return your call or email. Both are current investigators for Ampion. They offer some very good insights.
Bottom line, unless they can get away with an open label extension, you do not want to see THIS management running another double blinded trial. Let a larger Pharma do that.
..otherwise they would have given us the WOMAC #'s. Unreal. How do you go from 26% differentiation between Ampion & Saline in STRUT to that??
One can only hope that this "Gang That Couldn't Shoot Straight" turns Ampion over to another Pharma & management team. The drug works, the management team doesn't.
So to be clear - at 24 weeks you are pain free or mostly pain free?
Based on past correspondences with MM & the likelihood that STRIDE mirrors STRUT, it is highly unlikely that AMPE would accept any offer less than $20-$25/share.
...still over 9 million shares short - 25% of float.
I'm begging you to give it a rest. Ampion will prove to be superior to all the BS you post, and the market opportunity will be much greater than what you want to believe. Why do you continue to reference research from CITI that is stale and now irrelevant? Is it not obvious that Ampion MI has much greater efficacy than Ampion SI, and represents a vastly greater revenue opportunity, Ben Gay? Then you reference Jefferies, who basically pulled a chew and screw on AMPE, taking the secondary fees and belatedly coming out with a perfunctory and shallow research report to fulfill their obligation to initiate coverage. After the STEP failure, we never heard from them again. No surprise there. Again, we will see who is right and who is wrong. In the interim, stop posting your BS to a Board that mostly is unable to distinguish fact from your fiction.
You're an idiot to reference Citi & Jefferies research that is beyond stale - Jefferies hasn't written a note since STEP failure, and Citi hasn't since last Fall, and that analyst is now with Barclays. Not to mention those reports were written before the STRIDE trial with its MI regimen. "This is valued with HA's", I don't think so, Ben Gay. We will see who is right. In the interim, why don't you just sell, put yourself out of your misery, and get lost.
Oh, by the way, how's that OHRP investment working for you? Makes me nervous to think that I am investing along side you.
In past conversations with MM regarding OAK, his constant refrain was that "nothing works" in terms of treatments, and that includes Synvisc. No to mention it is starting to lose reimbursement. You can deduce that Synvisc will be obsoleted quickly if Ampion is approved. Then you can take the market for Synvisc and multiply that by 2 or 3 times given that there is huge OAK population for which Synvisc either doesn't work or isn't prescribed for.
That is why is see Ampion as a blockbuster. Blockbuster drugs are rare and don't come around very often. What is Pharma willing to pay for that?
....IF STRIDE mirrors STRUT, then you have a drug for OAK(a huge market that is growing every year with an unmet medical need for K-4's) that is unprecedented for pain relief & duration of action. Factor in the huge margins and 2 or 3 injections per year/patient, and it is not hard to see this as a $Billion drug. Then consider that Ampion could, in a relatively short period of time, be approved for other indications for other joints. Then maybe its a Multi $Billion drug.
What is Pharma willing to pay for that? Given the deals that have already transpired in the industry, $40.00 is a possibility.
..he is a wolf in a sheep's outfit, a short posing as a long. He has NEVER once posted anything regarding Ampion upside....just cut & paste articles ad nauseum whose aim is to continually cast doubt on Ampion.
And he talks about a "window of opportunity"?? Give me a break.